ROS1 and non-small cell lung carcinoma: Multiple phase I/II cohort trials (STARTRK-1, STARTRK-2, and ALKA-372-001) of entrectinib have reported the efficient activity and manageable safety of entrectinib in ROS1 + NSCLC patients.